Editorial: Natural products as drivers in drug development for neurodegenerative disorders

Joana Silva1, Rebeca Alvariño2, Márcia I. Goettert3,4, Hector J. Caruncho5 and Celso Alves1*

1MARE—Marine and Environmental Sciences Centre, Polytechnic of Leiria, Peniche, Portugal, 2Department of Pharmacology, Faculty of Veterinary, University of Santiago de Compostela, Lugo, Spain, 3Department of Pharmacology and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls Universität Tübingen, Tübingen, Germany, 4Cell Culture Laboratory, Postgraduate Programme in Biotechnology, University of Vale do Taquari Univates, Lajeado, Brazil, 5Division of Medical Sciences, University of Victoria, Victoria, BC, Canada

KEYWORDS
natural products (NP), neuroinflammation, oxidative stress, apoptosis, mechanisms of action, neuropharmacology, drug discovery, ethnopharmacology

The prevalence of neurological disorders (NDs) is a large and increasing health burden worldwide and is one of the emerging reasons for morbidity, mortality, and cognitive impairment in aging. Impact of NDs is expected to significantly increase in the next decades due to the progressive aging of the world society (Feigin and Vos, 2019). In the specific case of neurodegenerative process, it leads to malfunctions and cellular death, which seems to be triggered by a set of complex biological mechanisms, such as protein aberrant aggregation, mitochondrial dysfunction, oxidative stress, defective protein quality control, and degradation pathways, stress granules, and maladaptive immune response (Moujalled et al., 2021). Despite the advances achieved, the effectiveness of current drugs to control, delay, or block the NDs progression is still limited (Durães et al., 2018). Thus, the discovery and development of new therapeutic agents that can improve the currently therapeutic regimes are of utmost importance. Accordingly, a large focus has been placed on the potential of natural products (NPs) as new natural neuroprotective agents, essentially due to their scaffold diversity, structural complexity, and ability to activate several intracellular signaling pathways through distinct mechanisms of action while presenting fewer side-effects (Alghamdi et al., 2022).

Over the last decades, nature has revealed to be a prolific source of unparalleled structurally active metabolites, with a broad spectrum of biological activities, including antibacterial, antifungal, anticancer, antiinflammatory, antioxidant, anti-inflammatory, and neuroprotective properties (Grkovic et al., 2014; Newman and Cragg, 2020; Atanasov et al., 2021; Singla et al., 2021). To date, quite a wide range of
NPs classes have been isolated from terrestrial and marine organisms, including alcohols, alkaloids, amino acid derivatives, aromatic compounds, fatty acids, lactones, peptides, polyacetylenes, polyketides, quinones, quinolones, sphingolipids, sterols, terpenes, and terpenoids, among others (Newman and Cragg, 2020). Since those metabolites are produced as a response to physical and ecological pressures to ensure organisms survival and have presumably evolved over billions of years in close association with biological systems, they present high specificity and great affinity to interact with biological target structures, making them excellent candidates to inspire the development of new medicines, with minimal collateral effects and significant health benefits (Hong, 2011; Li et al., 2019).

The Research Topic here presented was focused on the potential of natural products (NPs) as scaffolds to inspire the development of new drugs for neurodegenerative disorders treatments, emphasizing the diversity of molecular targets and mechanistic effects. This topic gathered a collection of three critical reviews and four original research articles, with over 10,800 views and more than 2,200 article downloads, highlighting the capacity of NPs to target key players of signaling pathways related with NDs development, namely Alzheimer’s disease (AD), depression, and infectious diseases.

Fakhri et al. provide a review regarding the neuronal symptoms of emerging infectious diseases (EID) and underlying pathophysiological mechanisms. The capacity of NPs acting as multi-target agents on dysregulated pathways towards neuroprotection related with EID was investigated applying a mechanistic-based strategy.

Nowak et al. reported a detail review regarding the neuroprotective properties of *Ginkgo biloba* L. [Ginkgoaceae] and its most used standardized extract (EGb 761) on the intracellular signaling pathways related with AD pathogenesis hallmarks.

On the other hand, Piccialli et al. focused their review on the therapeutic potential of polyphenols and monoterpenes, two of the major chemical classes of natural products, in AD, reporting the intracellular signaling pathways activated by them.

Glycogen synthase kinase 3β (GSK3β) pathway have been associated to the pathophysiology of AD. Its permanent abnormal activation compromises the synaptic signals critical for learning and memory processes in AD, leading to memory impairment, increased production of Aβ, and inflammatory responses (Lauretti et al., 2020). Rodríguez-Urgellés et al. described the in vivo neuroprotective potential of meridianins, marine indole alkaloids, as GSK3β inhibitors. The treatments performed in 5xFAD mice exhibited a marked improvement of recognition memory and cognitive abilities avoiding the synaptic loss and reduced the neuroinflammatory processes.

The higher beneficial effects of trans ε-viniferin, a natural polyphenol biosynthesized by *Vitis vinifera* L. [Vitaceae], have been suggested comparing with the standard polyphenol resveratrol, due to its chemical structure and reduced catabolism (Boocock et al., 2007). Freyssin et al. reported the higher neuroprotective effects of viniferin compared to resveratrol an in vivo model of AD after a prolonged exposure, reducing amyloid load and deposits, partly preventing the cognitive decline and being more effective against glial reactivity.

Pan et al. studied the in vivo antidepressant effects of total triterpenes attained from a sclerotium of the polyporaceae fungus *Wolfiporia cocos* (TTWC) commonly used in traditional Chinese medicine to treat depression. TTWC treatment induced an antidepressant-like effect regulating the levels of neurotransmitters, hypothalamic-pituitary-adrenal (HPA) axis, and NLRP3 signaling pathway.

Yang et al. investigated the ability of Chinese medicinal plants (CMP) components to target serotonin receptor 5-HT1B, which is widely expressed in several of cognitive and psychiatric disorders, such as depression and AD (Gadgaard and Jensen, 2020). Emodin-8-O-β-D-glucopyranoside (EG) active ingredient displayed to be a selective agonist of 5-HT1B activating 5-HT1B–induced signaling pathway and modulating Aβ-related inflammatory process regulation and neural death resistance.

Altogether, the seven publications gathered in this topic provide a relevant overview of natural products as potential therapeutic neuroprotective agents, with special focus in AD, depression, and neuronal symptoms related with emerging infectious diseases.

**Author contributions**

All authors had a substantial, direct, and intellectual contribution to the development of the Research Topic and approved this publication.
Funding

CA acknowledges the support by the Portuguese Foundation for Science and Technology (FCT) through the strategic projects UIDB/04292/2020 and UIDP/04292/2020 granted to MARE—Marine and Environmental Sciences Centre, Associate Laboratory ARNET (LA/P/0069/2020), and CROSS-ATLANTIC (PTDC/BIA-OUT/29250/2017), co-financed by European Regional Development Fund (FEDER), through the Operational Programme for Competitiveness and Internationalization (COMPETE 2020). This work was also supported by FCT and CAPES cooperation agreement through project MArTics (FCT/DRI/CAPES 2019.00277. CBM).

Acknowledgments

The Topic Editors would like sincerely acknowledges the efforts provided by all authors that participated in this Research Topic, all reviewers that carefully reviewed the manuscripts, and the Frontiers in Pharmacology editorial office for their support and assistance.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Alghamdi, S. S., Saliman, R. S., Ajammar, N. A., Kahtani, K. M., Aljuth, D. A., Albadrani, G. M., et al. (2022). Natural products as novel neuroprotective agents; computational predictions of the molecular targets, ADME properties, and safety profile. *Plants* 11 (4), 549. doi:10.3390/plants1104549

Atanasov, A. G., Zotchev, S. B., Dirac, V. M., Orhan, I. E., Banach, M., Rollinger, J. M., et al. (2021). The international natural product SciencesNatural products in drug discovery: advances and opportunities. *Nat. Rev. Drug Discov.* 20, 200–216. doi:10.1038/s41573-020-00114-z

Boocock, D. J., Patel, K. R., Faust, G. E. S., Normolle, D. P., Marczylo, T. H., Crowell, J. A., et al. (2007). Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 848, 182–187. doi:10.1016/j.jchromb.2006.10.017

Durites, F., Pinto, M., and Sousa, E. (2018). Old drugs as new treatments for neurodegenerative diseases. *Pharmaceuticals* 11, 44. doi:10.3390/ph11020044

Feigin, V. L., and Vos, T. (2019). Global burden of neurological disorders: From global burden of disease estimates to actions. *Neuroepidemiology* 52, 1–2. doi:10.1159/000491597

Gadgaard, C., and Jensen, A. A. (2020). Functional characterization of 5-HT1A and 5-HT1B serotonin receptor signaling through G-protein-activated inwardly rectifying K+ channels in a fluorescence-based membrane potential assay. *Biochem. Pharmacol.* 175, 113870. doi:10.1016/j.bcp.2020.113870

Girkovic, T., Pouwer, R. H., Vial, M.-L., Gambini, L., Noel, A., Hooper, J. N. A., et al. (2014). NMR fingerprints of the drug-like natural-product space identify strichoctamidine A: A chemical probe to study Parkinson’s disease. *Angew. Chem. Int. Ed. Engl.* 53, 6070–6074. doi:10.1002/anie.201402239

Hong, J. (2011). Role of natural product diversity in chemical biology. *Curr. Opin. Chem. Biol.* 15, 350–354. doi:10.1016/j.cbpa.2011.03.004

Lauretti, E., Dincer, O., and Praticò, D. (2020). Glycogen synthase kinase-3 signaling in Alzheimer’s disease. *Biochim. Biophys. Acta. Mol. Cell Res.* 1867, 118664. doi:10.1016/j.bbamcr.2020.118664

Li, J., Long, X., Hu, J., Bi, J., Zhou, T., Guo, X., et al. (2019). Multiple pathways for natural product treatment of Parkinson’s disease: A mini review. *Phytomedicine* 60, 152954. doi:10.1016/j.phymed.2019.152954

Moujalld, D., Strasser, A., and Liddell, J. R. (2021). Molecular mechanisms of cell death in neurological diseases. *Cell Death Differ.* 28, 2029–2044. doi:10.1038/s41418-021-00814-y

Newman, D. J., and Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *J. Nat. Prod.* 83, 770–803. doi:10.1021/acs.jnatprod.9b01285

Singla, R. K., Agarwal, T., He, X., and Shen, B. (2021). Herbal resources to combat a progressive & degenerative nervous system disorder- Parkinson’s disease. *Curr. Drug Targets* 22, 609–630. doi:10.2174/1389450121999201013155202